Search research articles
Contact Us
Filters
Showing results (11-20 of 121) with videos related to
Page
of 13
Sort By:
Clinical Science and Molecular Medicine. Supplement
|
December 1, 1976
Aldosterone regulation in primary aldosteronism: differences between adenoma and bilateral hyperplasia
F Mantero, M Gion, D Armanini, et al.
Minerva Medica
|
June 8, 1979
[Primary hyperaldosteronism syndrome]
F Mantero, D Armanini, M Gion, et al.
The International Journal of Biological Markers
|
July 1, 1992
Cost/effectiveness ratio of carcinoembryonic antigen--importance of adequacy of routine requests of tumor markers
M Gion, A Rampazzo, R Mione, et al.
Anticancer Research
|
July 1, 1996
Dynamic use of tumor markers, rationale-clinical applications and pitfalls
M Gion, R Mione, P Barioli, et al.
Clinical Chemistry
|
June 1, 1990
Radioligand binding assay of epidermal growth factor receptor: causes of variability and standardization of the assay
R Dittadi, M Gion, A Brazzale, et al.
The Journal of Nuclear Medicine and Allied Sciences
|
October 1, 1990
Immunoprecipitation method for a radioligand binding assay of epidermal growth factor receptor
R Dittadi, M Gion, A Brazzale, et al.
The International Journal of Biological Markers
|
February 1, 2002
Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay
R Dittadi, M Zancan, A Perasole, et al.
The International Journal of Biological Markers
|
January 14, 2005
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer
S Meo, R Dittadi, L Peloso, et al.
Cancer Research
|
March 15, 1997
Detection of different estrogen receptor forms in breast cancer cytosol by enzyme immunoassay
R Dittadi, S Meo, B Amoroso, et al.
Clinical Chemistry
|
May 1, 1999
Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer
M Gion, R Mione, A E Leon, et al.
Page
of 13
Search research articles
Search
Showing results (11-20 of 121) with videos related to
Sort By:
Page
of 13
Clinical Science and Molecular Medicine. Supplement
|
December 1, 1976
Aldosterone regulation in primary aldosteronism: differences between adenoma and bilateral hyperplasia
F Mantero, M Gion, D Armanini, et al.
Minerva Medica
|
June 8, 1979
[Primary hyperaldosteronism syndrome]
F Mantero, D Armanini, M Gion, et al.
The International Journal of Biological Markers
|
July 1, 1992
Cost/effectiveness ratio of carcinoembryonic antigen--importance of adequacy of routine requests of tumor markers
M Gion, A Rampazzo, R Mione, et al.
Anticancer Research
|
July 1, 1996
Dynamic use of tumor markers, rationale-clinical applications and pitfalls
M Gion, R Mione, P Barioli, et al.
Clinical Chemistry
|
June 1, 1990
Radioligand binding assay of epidermal growth factor receptor: causes of variability and standardization of the assay
R Dittadi, M Gion, A Brazzale, et al.
The Journal of Nuclear Medicine and Allied Sciences
|
October 1, 1990
Immunoprecipitation method for a radioligand binding assay of epidermal growth factor receptor
R Dittadi, M Gion, A Brazzale, et al.
The International Journal of Biological Markers
|
February 1, 2002
Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay
R Dittadi, M Zancan, A Perasole, et al.
The International Journal of Biological Markers
|
January 14, 2005
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer
S Meo, R Dittadi, L Peloso, et al.
Cancer Research
|
March 15, 1997
Detection of different estrogen receptor forms in breast cancer cytosol by enzyme immunoassay
R Dittadi, S Meo, B Amoroso, et al.
Clinical Chemistry
|
May 1, 1999
Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer
M Gion, R Mione, A E Leon, et al.
Page
of 13